​

Stoke Therapeutics (STOK) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Stoke Therapeutics Revenue Highlights

Latest Revenue (Y)

$184.42M

Latest Revenue (Q)

$10.63M

Main Segment (Y)

License

Stoke Therapeutics Revenue by Period

Stoke Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$184.42M404.50%
2024-12-31$36.55M316.34%
2023-12-31$8.78M-29.22%
2022-12-31$12.40M100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Stoke Therapeutics generated $184.42M in revenue during NA 2025, up 404.50% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Stoke Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30$10.63M-23.05%
2025-06-30$13.82M-91.29%
2025-03-31$158.57M601.20%
2024-12-31$22.61M362.08%
2024-09-30$4.89M1.30%
2024-06-30$4.83M14.59%
2024-03-31$4.22M50.46%
2023-12-31$2.80M-15.30%
2023-09-30$3.31M-233.33%
2023-06-30$-2.48M-148.16%
2023-03-31$5.15M57.60%
2022-12-31$3.27M12.53%
2022-09-30$2.90M-10.09%
2022-06-30$3.23M7.70%
2022-03-31$3.00M100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Stoke Therapeutics generated $10.63M in revenue during Q3 2025, up -23.05% compared to the previous quarter, and up 220.08% compared to the same period a year ago.

Stoke Therapeutics Revenue Breakdown

Stoke Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
License$11.50M$29.40M
Service$4.60M$7.20M

Stoke Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (71.43%), and Service (28.57%).

Stoke Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
NVAXNovavax$1.12B$70.44M
BCRXBioCryst Pharmaceuticals$874.84M$159.40M
ARDXArdelyx$407.32M$110.33M
STOKStoke Therapeutics$184.42M$10.63M
WVEWave Life Sciences$42.73M$7.61M
ZBIOZenas BioPharma$10.00M-
UPBUpstream Bio$2.85M$683.00K
NTLAIntellia Therapeutics-$13.78M
PHVSPharvaris--
SYRESpyre Therapeutics--
ZYMEZymeworks$-27.11M$48.73M

STOK Revenue FAQ

What is Stoke Therapeutics’s yearly revenue?

Stoke Therapeutics's yearly revenue for 2025 was $184.42M, representing an increase of 404.50% compared to 2024. The company's yearly revenue for 2024 was $36.56M, representing an increase of 316.34% compared to 2023. STOK's yearly revenue for 2023 was $8.78M, representing a decrease of -29.22% compared to 2022.

What is Stoke Therapeutics’s quarterly revenue?

Stoke Therapeutics's quarterly revenue for Q3 2025 was $10.63M, a -23.05% decrease from the previous quarter (Q2 2025), and a 117.25% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $13.82M, a -91.29% decrease from the previous quarter (Q1 2025), and a 186.01% increase year-over-year (Q2 2024). STOK's quarterly revenue for Q1 2025 was $158.57M, a 601.20% increase from the previous quarter (Q4 2024), and a 3661.12% increase year-over-year (Q1 2024).

What is Stoke Therapeutics’s revenue growth rate?

Stoke Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 2000.46%, and for the last 5 years (2021-2025) was 0%.

What are Stoke Therapeutics’s revenue streams?

Stoke Therapeutics's revenue streams in c 25 are License, and Service. License generated $11.5M in revenue, accounting 71.43% of the company's total revenue, down -60.88% year-over-year. Service generated $4.6M in revenue, accounting 28.57% of the company's total revenue, down -36.11% year-over-year.

What is Stoke Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Stoke Therapeutics was License. This segment made a revenue of $11.5M, representing 71.43% of the company's total revenue.